How a Common Nutrient Helps Cancer Cells Hide from Death

By Marwan Ben A
Vitamin B2’s Dark Side: How a Common Nutrient Helps Cancer Cells Hide from Death


Vitamin B2 can strengthen cancer cells by helping them resist ferroptosis, the body’s natural cell death defense.
Researchers discovered that cancer cells exploit Vitamin B2 metabolism to block ferroptosis, a natural mechanism of cellular destruction.

We are often taught that vitamins are the ultimate protectors of our health. Vitamin B2, also known as riboflavin, is an essential nutrient found in dairy products, eggs, meat, and green vegetables. Because the human body cannot produce it, we must consume it through our diet to support energy metabolism and provide the enzymatic cofactors necessary to protect our cells from oxidative stress.

However, recent findings have revealed a biological paradox: the very same nutrient that maintains the integrity of healthy tissue also acts as a sophisticated shield for tumors. Researchers at the Rudolf Virchow Centre (RVZ) for Integrative and Translational Bioimaging at the University of Würzburg have discovered that cancer cells weaponize Vitamin B2 to evade "programmed cell death," the body’s primary mechanism for cleaning up dangerous or damaged cells before they can form a malignancy.

Ferroptosis: When Cells Rust from the Inside Out

The core of this discovery involves a specific type of programmed cell death known as ferroptosis. Unlike traditional apoptosis—a tidy, pre-programmed cellular "suicide"—ferroptosis is an iron-driven process of destruction. It occurs when iron-dependent lipid peroxidation overwhelms the cell's defenses, essentially causing the fats in the cell membrane to "rust." This oxidative damage triggers a catastrophic collapse of the cell's structural integrity.

Because ferroptosis can effectively eliminate malignant cells, it acts as a powerful natural suppressor of cancer. Consequently, the most aggressive tumors have evolved complex ways to stop this "rusting" process in its tracks.

“Vitamin B2 plays a crucial role in protecting cancer cells from ferroptosis, a special form of programmed cell death,” explains Vera Skafar, a PhD student at the Rudolf Virchow Centre.

FSP1: The NADH-Dependent Bodyguard

A primary architect of this evasion is a protein originally identified as AIFM2 (Apoptosis-Inducing Factor 2). In a significant paradigm shift for oncology, researchers at UC Berkeley and the Helmholtz Institute discovered that its name was actually a misnomer; rather than inducing death, it is a potent protector against it. The protein was subsequently re-classified as Ferroptosis Suppressor Protein 1 (FSP1).

FSP1 functions as an NADH-dependent oxidoreductase. It acts like a high-tech sentry on the cell's plasma and organelle membranes, where it reduces molecules like ubiquinone (Coenzyme Q10) into ubiquinol. This reduced form, ubiquinol, serves as a lipophilic antioxidant that traps radicals and halts lipid peroxidation before it can reach lethal levels.

Tumors often secure this defense through the NRF2 pathway—the master regulator of antioxidant responses. Because FSP1 is an NRF2-targeted gene, many cancers overexpress this protein, creating a nearly impenetrable shield against ferroptosis.

The Flavoprotein Connection: Why FSP1 Needs B2

The link between Vitamin B2 and cancer survival is purely structural. FSP1 is a "flavoprotein," meaning it is essentially an empty shell without a specific helper molecule: Flavin Adenine Dinucleotide (FAD). FAD is a metabolic derivative of Vitamin B2.

Without FAD to facilitate the transfer of electrons, FSP1 cannot reduce ubiquinone to ubiquinol, and the antioxidant shield collapses. Research at the Rudolf Virchow Centre using genome editing has confirmed this metabolic dependency: when Vitamin B2 is deficient, the FAD-dependent FSP1 protein becomes non-functional, and cancer cells become drastically more vulnerable to ferroptosis. It is a striking example of tumor adaptation; cancer cells "boost" natural nutrient pathways, hijacking the riboflavin from our healthy diets to fortify their own biochemical defenses.

Roseoflavin: The Trojan Horse Strategy

Understanding the B2-dependency of FSP1 offers a new roadmap for therapy. Currently, researchers use direct FSP1 inhibitors like iFSP1, FSEN1, and icFSP1 to sensitize cells to ferroptosis. However, a specific drug capable of switching off the B2-metabolic pathway itself is still being developed.

To prove the feasibility of this strategy, researchers successfully employed roseoflavin, a natural bacterial analog of riboflavin. Roseoflavin acts as a "Trojan Horse"; because its structure is nearly identical to B2, it is absorbed by the cancer cell and integrated into the FSP1 protein, where it displaces the natural FAD cofactors. This "clogs" the protein's machinery, rendering the shield useless.

“It turned out that roseoflavin triggers ferroptosis in low concentrations... our experiments show the feasibility of this concept,” says Professor Friedmann Angeli, leader of the Research Group for Translational Cell Biology at the University of Würzburg.

Clinical Implications Beyond Oncology

The upregulation of FSP1 in several cancers correlates with poor patient prognosis and high resistance to treatment. Yet, the B2-FSP1 connection is a double-edged sword that extends far beyond oncology into the realm of general organ health.

In conditions like neurodegenerative diseases, organ transplantation, and ischemia-reperfusion injury, the problem is not too little cell death, but too much. During a heart attack or a transplant, the sudden return of oxygenated blood triggers a surge of lipid peroxidation. In these contexts, we actually want to boost the B2-FSP1 shield to save healthy tissue. This research suggests that managing B2 metabolism could allow clinicians to toggle the ferroptosis switch—turning it "on" to kill tumors and "off" to protect the brain and heart.

The Future of Precision Nutrition and Therapy

This work is a cornerstone of the DeciFerr project, an ERC-funded initiative dedicated to deciphering and exploiting ferroptosis in the fight against cancer. As medicine shifts toward precision oncology, the focus is moving toward therapies that target the unique metabolic vulnerabilities of a specific tumor.

The discovery invites a deeper reflection on the complexity of our biology. In our quest to fortify our bodies with essential vitamins, have we overlooked how the most "healthy" molecules might be weaponized by the very diseases we aim to prevent? The future of cancer therapy may lie not in broad-spectrum toxins, but in our ability to master the delicate metabolic balance of the nutrients we consume every day.

References